Pathogens (Feb 2022)

Evaluation of Eosinophilic Cationic Protein as a Marker of Alveolar and Cystic Echinococcosis

  • Julian Frederic Hotz,
  • Klaus Kaczirek,
  • Stefan Stremitzer,
  • Fredrik Waneck,
  • Herbert Auer,
  • Thomas Perkmann,
  • Manuel Kussmann,
  • Philipp Karl Bauer,
  • Rui-Yang Chen,
  • Richard Kriz,
  • Heinz Burgmann,
  • Michael Ramharter,
  • Heimo Lagler

DOI
https://doi.org/10.3390/pathogens11020261
Journal volume & issue
Vol. 11, no. 2
p. 261

Abstract

Read online

Echinococcosis is a neglected zoonotic disease and a worldwide public health problem caused by infection with the larval stages of taeniid cestodes of the genus Echinococcus. In vitro studies have demonstrated a protoscolecidal effect of eosinophilic cationic protein (ECP), a granule protein of eosinophilic granulocytes, against E. granulosus. Therefore, the main objective of this study was to evaluate ECP as a biomarker in the treatment of alveolar echinococcosis (AE) and cystic echinococcosis (CE). Data were collected retrospectively from the Vienna Echinococcosis Cohort over 7 years until December 2020. Altogether, 32 patients (16 AE and 16 CE) were included. In the selected patients, serum ECP values were compared before and after the beginning of an operative and/or benzimidazole (BMZ) therapy. Mean ECP serum levels before intervention were significantly (p p p < 0.05) correlation of k = 0.56 with PET–CTI. Based on the significant decrease after operative and/or BMZ treatment and the correlation with clinical markers such as PET–CTI, it is recommended to investigate ECP more intensively as a marker of AE and CE in prospective studies with larger cohorts.

Keywords